

1 Vaccination coverage and adverse events following a reactive vaccination
2 campaign against hepatitis E in Bentiu displaced persons camp, South Sudan

3 **Authors**

4 Robin Nesbitt^{1*}, Vincent Kinya Asilaza², Etienne Gignoux^{1,3}, Aybüke Koyuncu^{1,4}, Priscillah Gitahi²,
5 Patrick Nkemenang², Jetske Duncker², Zelig Antier², Melat Haile³, Primitive Gakima³, Joseph Wamala⁵,
6 Frederick Beden Loro⁵, Duol Biem⁶, Monica Rull³, Andrew S. Azman^{3,4,7,8}, John Rumunu⁶, Iza
7 Ciglonecki³

8 **Affiliations**

9 ¹Epicentre, Paris
10 ²Medecins Sans Frontières South Sudan
11 ³Medecins Sans Frontières Switzerland
12 ⁴Johns Hopkins University Bloomberg School of Public Health
13 ⁵World Health Organization South Sudan
14 ⁶Ministry of Health, South Sudan
15 ⁷Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland
16 ⁸Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Geneva, Switzerland
17 *Corresponding author, email: robin.nesbitt@epicentre.msf.org

18

19 **Abstract**

20 **Introduction:** Hepatitis E (HEV) genotypes 1 and 2 are a common cause of jaundice and acute viral
21 hepatitis that can cause large-scale outbreaks. HEV infection is associated with adverse fetal
22 outcomes and case fatality risks up to 26% among pregnant women. An efficacious three-dose
23 recombinant vaccine (Hecolin[®]) has been licensed in China since 2011 but until 2022, had not been

24 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
used for outbreak response despite a 2015 WHO recommendation. The first ever mass vaccination

25 campaign against hepatitis E in response to an outbreak was implemented in 2022 in Bentiu
26 internally displaced persons camp in South Sudan targeting 27,000 residents 16-40 years old,
27 including pregnant women.

28 **Methods:** We conducted a vaccination coverage survey using simple random sampling from a
29 sampling frame of all camp shelters following the third round of vaccination. For survey participants
30 vaccinated in the third round in October, we asked about the onset of symptoms experienced within
31 72 hours of vaccination. During each of the three vaccination rounds, passive surveillance of adverse
32 events following immunisation (AEFI) was put in place at vaccination sites and health facilities in
33 Bentiu IDP camp.

34 **Results:** We surveyed 1,599 individuals and found that self-reported coverage with one or more dose
35 was 86% (95% CI 84-88%), 73% (95% CI 70-75%) with two or more doses and 58% (95% CI 55-61%)
36 with three doses. Vaccination coverage did not differ significantly by sex or age group. We found no
37 significant difference in coverage of at least one dose between pregnant and non-pregnant women,
38 although coverage of at least two and three doses was 8 and 14 percentage points lower in pregnant
39 women. The most common reasons for non-vaccination were temporary absence or unavailability,
40 reported by 60% of unvaccinated people. Passive AEFI surveillance captured few mild AEFI, and
41 through the survey we found that 91 (7.6%) of the 1,195 individuals reporting to have been
42 vaccinated in October 2022 reported new symptoms starting within 72 hours after vaccination, most
43 commonly fever, headache or fatigue.

44 **Conclusions:** We found a high coverage of at least one dose of the Hecolin vaccine following three
45 rounds of vaccination, and no severe AEFI. The vaccine was well accepted and well tolerated in the
46 Bentiu IDP camp community and should be considered for use in future outbreak response.

48 **Introduction**

49 Hepatitis E virus (HEV) genotypes 1 and 2 have been reported throughout the world, though
50 outbreaks have mostly been reported in populations with precarious access to water and sanitation,
51 such as refugee and displaced persons camps. HEV g1/g2 infection causes jaundice and is usually self-
52 limiting, although in a small proportion of cases, infection can cause acute fulminant hepatitis (1).
53 HEV g1/g2 infection is associated with negative pregnancy outcomes such as stillbirth (2) and
54 maternal clinical case fatality ratios of up to 26% among pregnant women (3–5), particularly in the
55 third trimester. It was estimated that there were 3.4 million symptomatic cases in 2005 (6), however
56 limited access to diagnostics and lack of surveillance means that the burden of morbidity and
57 mortality is likely underestimated.

58 Hecolin® (HEV 239, Inovax, China) is a recombinant vaccine based on HEV genotype 1 and has been
59 licensed in China since 2011 for adults over 16 years. In a phase three trial with more than 110,000
60 participants, Hecolin demonstrated an efficacy of 100% (95% CI 72.2- 100) for the full three-dose
61 schedule over the first 19 months (7) and with 86.8% (95% 71-94%) efficacy over the first 4.5 years
62 after vaccination (8). Although not recommended for use in routine immunization programmes, the
63 WHO issued a statement in 2015 and again in 2021 recommending the use of hepatitis E vaccine
64 (HEV 239, Hecolin®) to mitigate or prevent outbreaks, including the vaccination of pregnant women
65 (9,10). Until 2022, the vaccine had not been used in response to an outbreak.

66 In March 2022, the Ministry of Health (MoH) in South Sudan and MSF implemented the first mass
67 reactive vaccination campaign against hepatitis in Bentiu internally displaced persons (IDP) camp,
68 South Sudan (11). Bentiu IDP camp was established in 2014 as a Protection of Civilians site at a
69 United Nations Mission in South Sudan base in response to conflict in Unity State. Cases of hepatitis E
70 were detected in the camp since it was established, with large outbreaks occurring in 2015 (2189
71 cases reported) and in 2016 (924 cases reported). HEV transmission continued despite increasingly
72 formalised infrastructure and coordinated humanitarian response, and an outbreak was declared by

73 the MoH in August 2021. In response, the MoH and MSF conducted a vaccination campaign in three
74 rounds in March, April and October 2022. MSF and the MoH put in place a series of operational
75 research studies aimed at documenting the feasibility, effectiveness, and safety of the vaccination.
76 The vaccination campaign targeted 26,848 residents of Bentiu IDP camp aged 16-40 years old,
77 including pregnant women. This age target was chosen to benefit from the limited vaccine doses
78 available because the vaccine is not registered for use in children younger than 16 years; the upper
79 limit was chosen based on pre-vaccination incidence rate estimates, which were lower among older
80 adults. Individuals with jaundice, known chronic liver disease, immunodeficiency or other acute
81 severe illness were excluded from vaccination. During the second and third rounds, the vaccine was
82 offered to anyone within the target group (16-40 years old and residence in Bentiu IDP camp),
83 regardless of whether they received a previous dose or not. The campaign used a combined strategy
84 of fixed vaccination points and mobile vaccination teams at markets, food distribution points and
85 water points (11). The administrative coverage (i.e., number of doses delivered divided by the
86 estimated target population size) was over 90% for all three vaccination rounds: the first round in
87 March reached 24,469 people (91% of the target), the second round in April reached 25,434 people
88 (95% of the target), the last round in October reached 30,264 people (113% of the target, Table 1).
89 Here we describe the results of a survey aimed to estimate vaccination coverage within the targeted
90 population immediately after the third and final vaccination round. We additionally aimed to
91 document adverse events following immunization (AEFI) via passive surveillance and estimate the
92 proportion of people experiencing new symptoms after vaccination in the survey.

93 **Methods**

94 *Representative Vaccination Coverage Survey*

95 Following the third round of vaccination, we conducted a coverage survey with a target sample size
96 of 836 individuals, to allow for 5% precision around the assumed three-dose vaccine coverage
97 estimate of 50% considering a design effect of 2 due to within household correlation in coverage. We

98 estimated that 590 households were required to achieve this sample size based on an average
99 household size of 7 people, 2 vaccine-eligible individuals 16-40 years per household, and a 10%
100 refusal ratio. The target population for the survey was vaccine-eligible individuals: 16-40 years old at
101 the time of the survey conducted immediately after the third and final vaccination round, resident of
102 Bentiu IDP camp (excluding Bentiu town and other communities outside the camp), and without
103 jaundice, known chronic liver disease, immunodeficiency or any acute illness during the vaccination
104 campaign. All vaccine-eligible individuals in each household were eligible for inclusion in the survey.
105
106 In total, 600 shelters were selected by simple random sampling without replacement using the R
107 sampling package `srswor` from a sampling frame of all 12,139 shelters in Bentiu IDP camp, provided
108 by IOM camp management. All households living in the selected shelter were eligible for inclusion.
109
110 A team of seven data collectors and one supervisor were trained and interviews took place for a total
111 of 11 days (28 October until 9 November, excluding Sundays). For each household, after obtaining
112 verbal consent from the head of household, we asked about all members of the household, including
113 age and sex, to determine household size and identify vaccine-eligible individuals. For household
114 members 16-40 years old at the time of survey, vaccination status was determined through
115 interviews and checking vaccination cards. Vaccination status was determined through interviews
116 and checking vaccination cards, responses were accepted from the head of household or a delegated
117 person over 18 years old if vaccine-eligible individuals were not present at time of interview.
118 Photographs were taken of vaccination cards, when available and consented. The team conducted
119 up to two revisits if household residents were absent on the day of the interview.
120
121 Questionnaires were conducted using ODK Collect (<https://getodk.org/>) on mobile devices. Data
122 were uploaded to a secure server every evening; quality checks were done and feedback was given
123 to the data collection team daily.

124 *Pharmacovigilance / Adverse Events Following Immunisation (AEFI)*

122 Prior to the first round of vaccination, passive surveillance of adverse events following immunisation
123 (AEFI) was put in place at all 5 primary health clinics inside Bentiu IDP camp, the MSF hospital and at
124 the vaccination sites. Paper registers and forms were distributed, and facility staff were trained to
125 complete the register and the reporting forms when a patient reported symptoms following
126 vaccination. During and after each vaccination round, MSF staff visited the PHCCs to collect the
127 completed registers and forms. During the first round, vaccinees were asked to stay at the sites for
128 15 minutes observation period after vaccination. As the vaccination campaign became more mobile
129 in the subsequent rounds, individuals were not required to wait at the site, they were instead
130 encouraged to go to the clinic for any symptoms. Passive AEFI surveillance systems likely do not
131 capture mild illness; we therefore asked survey respondents reporting to have been vaccinated in the
132 third vaccination round whether they experienced the onset of new symptoms within 72 hours of
133 vaccination.

134 *Statistical analysis*

135 All indicators (i.e., sex, age, and demographic characteristics) were calculated as proportions, and
136 differences in proportions were evaluated using Pearson χ^2 tests. Vaccination coverage, 95%
137 confidence intervals (95% CI), considering household clustering, and household design effects were
138 estimated using the survey package in R.

139 **Ethics**

140 Ethical approval was granted for this survey from the MSF ERB and by the South Sudan Ministry of
141 Health Research Ethics Board as part of the study protocol titled: “Effectiveness, safety and feasibility
142 of recombinant hepatitis E vaccine HEV 239 (Hecolin) during an outbreak of hepatitis E in Bentiu,
143 South Sudan.” Approval numbers are MSF ERB #2167 and RERB-MOH # 54/27/09/2022.

144 All participants provided verbal informed consent before participating in the interview.

145 **Results**

146 *Survey Population*

147 From the 600 shelters randomly selected for interview, 5 (0.8%) were abandoned, 34 (5.7%) were
148 absent after two revisits and 1 (0.17%) household refused to participate. In total, we conducted
149 interviews at 560 shelters (95% of the target) including 4,057 individual residents. Among them,
150 1,669 (200% of the target sample size) vaccine-eligible individuals were identified. The mean shelters
151 size was 7.2, with a reported average of 4.2 vaccine-eligible individuals aged 16-40 years per shelter.
152 Out of 1,669 vaccine-eligible individuals, 1,599 (95%) reported their vaccination status.

153 The person responding to the interview was the head of household or a delegated adult for 84% of
154 included individuals overall (this includes delegated reporting for children, counted as members of
155 each household), and 68% of vaccine-eligible individuals. This differed by sex as women were more
156 likely to be found at home, with 43% of women responding directly compared to 17% of men.

157 *Previous hepatitis E infection*

158 Overall few individuals reported previous jaundice or hepatitis E infection (n=64, 1.58%) since 2014
159 (when Bentiu IDP camp was established). Among those, 89% reported seeking care, most frequently
160 at the MSF hospital (75%, n=48).

161 **Coverage results**

162 We estimate complete coverage with three doses of Hepatitis E vaccine among the vaccine-eligible
163 population to be 58% (95% CI 55-61, Design effect [DEFF]=1.7), two dose coverage was 14.8% (95% CI
164 13.0-16.7%, DEFF=1.2) and one dose coverage was 13.6% (95% CI 11.7-15.6%, DEFF= 1.3) (Table A1).
165 This translates into 86% (95% CI 84-88, DEFF =1.6) of the target population having at least one dose,
166 and 73% (95% CI 70-75%, DEFF =1.6) having at least two doses (Table 3). Among those reporting to
167 have been vaccinated, less than half were able to provide a vaccination card (Table 3 and A1).

168 We found no significant differences in vaccination coverage by sex, age-group or by location of
169 residence within the camp (Table 4, Figure 1, Figure 2). Among 118 pregnant women 117 had known

170 vaccination status, vaccination coverage with at least 2 doses and complete 3 dose vaccination
171 coverage were significantly lower than among non-pregnant women (at least 2 doses: 66% (95% CI
172 57-74) vs non-pregnant women 74% (95% CI 71-78), $p=0.05$, 3 doses: 43.5% (95% CI 34.0 – 53.2) vs.
173 non-pregnant women 57.5% (95% CI 53.7 – 61.5), $p=0.006$, Table 4).

174 We conducted a sensitivity analysis including only individuals who reported directly for themselves
175 and found similar overall vaccination coverage for partial and complete vaccination (Table A2).
176 Similarly in a second sensitivity analysis excluding 40-year-olds to account for possible misreporting
177 of age, we also found similar vaccination coverage (Table A3).

178 According to the population distribution in selected households participating in the survey, the
179 vaccine-eligible population accounts for 41% of the total camp population (Table 2, Figure A1). The
180 high coverage among the eligible population therefore results in only 35% partial coverage with at
181 least one dose, 30% with at least two doses and 24% with the full three doses in the full camp
182 population.

183 **Reasons for non-vaccination**

184 The most common reasons for non-vaccination were absence or unavailability, given by 60% of
185 unvaccinated people, 80% of those who missed their second dose and 77% of those who missed their
186 third dose (Table 5). Not living in Bentiu IDP camp at the time of previous vaccination rounds was
187 reported by 20% of non-vaccinated individuals, 27.5% of those with one dose and 11.6% of those
188 with two doses. The proportion of individuals not vaccinated due to illness at the time of the
189 campaign ranged from 2.8% among individuals not vaccinated at all to 10.7% among individuals with
190 two doses, and for some, this illness was detected at the vaccination site (Table 5).

191 Fear of needles was more commonly cited as a reason for non-vaccination than a fear of side effects
192 or the perception that the vaccine is dangerous (Table 5). Fears or concerns were more common
193 among those not vaccinated at all (17.5%) than individuals vaccinated at least once (7%, Table 5).

194 Few individuals reported that getting sick with hepatitis E is not serious as a reason for non-
195 vaccination.

196 Among the 66 pregnant women who were not fully vaccinated, the distribution of reasons for non-
197 vaccination were similar to the non-pregnant population; most pregnant women reported that non-
198 vaccination was related to absence (60%), while 9% missed a dose because of feeling sick due to
199 pregnancy. Some did explicitly state fears related to side effects, fertility or pregnancy (6%), or fear
200 of needles (3%), and one woman reported that she did not believe the vaccine was effective.

201 **Pharmacovigilance**

202 *Passive AEFI surveillance*

203 Overall, the passive AEFI surveillance system detected 11 events after vaccination: two cases of fever
204 after the first round of vaccination in March; none after round two in April and nine after the third
205 round of vaccination in October.

206 Among survey participants reporting AEFI after the third round, 7 (78%) were female, 1 (11%) was
207 male and 1 (11%) sex was not documented; age ranged from 24 to 45 years, surpassing the upper
208 limit of age eligibility for vaccination. The AEFI was reported after the third dose for 6 (67%) people,
209 after the first or second dose for one person each and after unknown number of doses for one
210 person. The events included 4 local reactions, 1 allergic reaction, 1 with fever, joint pain and
211 vomiting, 2 others with details not specified and one pregnant woman with abdominal cramping. The
212 pregnant woman was admitted for observation to the MSF hospital and discharged in good condition
213 after two hours. All individuals detected through this system were documented to have recovered.

214 *Survey*

215 Overall, 91 (7.6%) of 1,195 individuals who reported receiving a dose of the Hecolin vaccine in
216 October 2022 (3rd round) reported a new symptom in the 72 hours after receiving the vaccine.
217 Women more frequently reported experiencing new symptoms than men (73 (10%), vs. 18 (3.7%)
218 $p < 0.001$).

219 Local reactions were reported less frequently than systemic reactions, with 11 (12%) individuals
220 reported local pain around injection site, 3 (3.3%) individuals reported rash, and 2 (2.2%) reported
221 local swelling around injection site (Table 6). Fever was the most common symptom reported by 68
222 (74.7% of individuals with symptoms), followed by headache (32%) and fatigue and general weakness
223 (23%). In the “other” category, symptoms reported included “pain in the throat” (n=1), “sleeping”
224 (n=4), “tested positive for malaria” (n=4), “back pain” (n=2), “heart burn” (n=3), and “reported
225 miscarriage next day” (n=1). No hospitalisations or deaths were reported.

226 We conducted a sensitivity analysis including only individuals self-reporting symptoms after
227 vaccination; we found an almost two-fold higher incidence of AEFI overall (14.3%, n=58/407
228 compared to 7.6% n=91/1,195, p<0.001) and no significant difference in reported symptoms by sex
229 (11.8% among men vs. 14.9% among women, p=0.461).

230

231 **Discussion**

232 Our survey following the first mass reactive vaccination campaign in Bentiu IDP camp found that the
233 hepatitis E vaccine was highly accepted, we estimate that 86% (95% CI 84-88%) of the vaccine-eligible
234 population had at least one dose, 73% (95% CI 70-75) had two or more doses and 58% (95% CI 55-
235 61%) had the complete three dose schedule. There were no significant differences in vaccination
236 coverage by age, sex, or camp sector of residence.

237 Most reasons for non-vaccination were related to absence rather than fear of needles or side effects
238 reflecting a general positive attitude towards vaccination in the community. Although the campaign
239 took place during the daytime, vaccination started early in the morning and continued the weekends,
240 and unavailability during the hours of the vaccination campaign was less frequently the reason for
241 non-vaccination. Population mobility is a challenge for accurately estimating population size and
242 providing a multi-dose vaccination schedule over a six-month period. Among individuals who had one
243 dose, around one third reported not residing in Bentiu IDP camp during the prior campaigns and half

244 were temporarily away. Temporary absence was common accounting for over 50% of non-
245 vaccination among individuals vaccinated at least once, and 55% among those with two doses. Many
246 individuals were able to get only one dose during the last round in October because they returned to
247 Bentiu after the second round of vaccination in April. With limited employment opportunities and
248 food availability in Bentiu IDP camp, residents frequently seek opportunities outside the camp, and
249 many individuals maintain a second residence in their county of origin. This may partly explain the
250 discrepancy in administrative and survey estimates of coverage, however, the similar estimates for
251 the third dose (53% administrative coverage third dose vs. 58% survey estimate) likely reflect the real
252 coverage among the population present at the time.

253 In our study, we captured few AEFI by passive surveillance at vaccination sites and health facilities,
254 whereas the inclusion of questions about symptoms after vaccination revealed more symptoms.
255 Overall, 7.6% of individuals vaccinated in October experienced at least one new symptom in the 72
256 hours after vaccination. Either individuals did not seek care for the symptoms reported in the survey,
257 or we did not capture them in our surveillance system. Both care-seeking and reporting may be
258 related to the severity of symptoms, and we hypothesize that more severe events would have been
259 more likely captured by the surveillance and reported in the survey. We were unable to investigate
260 the relatedness of the reported new symptom to the vaccine or categorize the type or severity of the
261 symptoms in the survey and consider all as possible vaccine reactions. From the survey results, we
262 estimated an incidence of local reactions of 1.4% and 11.7% systemic reactions. However, the AEFI
263 assessment in our survey was a one-time interview conducted a mean of 23 days after vaccination
264 and we accepted responses from a delegate. We found higher incidence of AEFI when looking only at
265 individuals self-reporting their symptoms in the survey.

266 In the Hecolin phase 3 clinical trial, all participants were observed for 30 minutes after each vaccine
267 dose (1). A reactogenicity subset in both the vaccine and placebo groups were visited seven times at
268 home at between 6 hours and 28 days after each dose. The remaining participants were asked to

269 report any adverse events to a local clinic within one month of each vaccine dose. Both active and
270 passive follow-up estimated a higher incidence of local adverse reactions in the Hecolin vaccine
271 group compared to placebo (active follow-up: 13.5% Hecolin vs 7.5% placebo; passive follow-up:
272 Hecolin 2.8% vs. 1.9% placebo) but a similar incidence of systemic adverse reactions in both groups
273 (active follow-up: 20.3% Hecolin vs 19.8% placebo; passive follow-up: 1.9%). In our study, we found
274 an incidence of systemic reactions (11.7%) higher than in the clinical trial passive follow-up, but
275 lower than in the active follow-up. These systemic reactions (i.e. fever, headache, fatigue) could
276 reflect the different measurement approach or alternatively, a higher burden of other illnesses (e.g.
277 malaria) in the Bentiu IDP camp population compared to the clinical trial population in China.

278 A major limitation of this survey is the high proportion of delegate respondents. This is a challenge in
279 conducting a rapid survey after an intervention in a mobile adult working-age population. When
280 restricting the analysis to people self-reporting only, we found a similar overall vaccination coverage,
281 but a higher incidence of AEFI. This higher incidence of AEFI however, remains comparable with what
282 was reported in Hecolin clinical trials. We conducted the survey soon after the end of the third-round
283 campaign, with interviews a median of 23 days (range 3 – 36 days) after respondents were
284 vaccinated in the third round. There were multiple vaccination campaigns conducted in Bentiu IDP
285 camp in 2022, including for SARS-CoV-2, cholera and measles and it is possible that individuals
286 reported vaccination for a different antigen. To mitigate this risk, interviewers showed pictures of the
287 Hecolin vaccine, whose single dose presentation is unique.

288 Vaccine confidence and acceptance is context specific and varies based on antigen and approach
289 (i.e., reactive or routine vaccination), and should be explored using qualitative methods. The rapid
290 deployment of new COVID-19 vaccines, the global scale of the COVID-19 pandemic and the
291 proliferation of rumours through social media contributed to a context of heightened vaccine
292 hesitancy in general during the campaign period (12). Nevertheless, we found a high uptake of the
293 Hecolin vaccine among the eligible population in Bentiu, perhaps reflecting the almost decade-long

294 transmission of hepatitis E in Bentiu IDP camp. Due to limited vaccine and license restrictions, this
295 high coverage among the target population corresponds to only 35% coverage with at least one-
296 dose, and 24% complete dose schedule coverage in the full camp population. If the safety of the
297 vaccine in children under the age of 16 years old were established, revision of license restrictions to
298 include children under 16 years old could protect more of the population at risk in this setting.

299 **Conclusion**

300 We found a high coverage of at least one dose of the Hecolin® vaccine among the eligible population
301 following three rounds of vaccination, and no severe adverse events following immunisation. We
302 demonstrate that the vaccine was well accepted and well tolerated in the Bentiu IDP camp
303 community after the first mass reactive vaccination campaign. To maintain high coverage over time,
304 providing vaccines outside of mass reactive vaccination campaigns would allow the highly mobile
305 population to be vaccinated according to their own timeline and help to prevent future outbreaks.

306 **Acknowledgments**

307 We thank the community of Bentiu IDP camp for their participation in the survey. We thank all the
308 survey team members who conducted the interviews. We thank the Bentiu IDP camp management
309 and health partners, including the state ministry of health and primary health clinics for their
310 support.

311 **References**

- 312 1. Kamar N, Izopet J, Pavio N, Aggarwal R, Labrique A, Wedemeyer H, et al. Hepatitis E virus
313 infection. *Nat Rev Dis Primer*. 2017 Nov 16;3(1):1–16.
- 314 2. Bigna JJ, Modiyinji AF, Nansseu JR, Amougou MA, Nola M, Kenmoe S, et al. Burden of hepatitis E
315 virus infection in pregnancy and maternofetal outcomes: a systematic review and meta-analysis.
316 *BMC Pregnancy Childbirth*. 2020 Jul 28;20(1):426.

- 317 3. Bergløv A, Hallager S, Weis N. Hepatitis E during pregnancy: Maternal and foetal case-fatality rates
318 and adverse outcomes-A systematic review. *J Viral Hepat*. 2019 Nov;26(11):1240–8.
- 319 4. Koyuncu A, Mapemba D, Ciglenecki I, Gurley ES, Azman AS. Setting a Course for Preventing
320 Hepatitis E in Low and Lower-Middle-Income Countries: A Systematic Review of Burden and Risk
321 Factors. *Open Forum Infect Dis*. 2021 Jun;8(6):ofab178.
- 322 5. Amany G, Kizito S, Nabukenya I, Kalyango J, Atuheire C, Nansumba H, et al. Risk factors, person,
323 place and time characteristics associated with Hepatitis E Virus outbreak in Napak District,
324 Uganda. *BMC Infect Dis*. 2017 Jun 26;17(1):451.
- 325 6. World Health Organization. Hepatitis E [Internet]. [cited 2023 Mar 7]. Available from:
326 <https://www.who.int/news-room/fact-sheets/detail/hepatitis-e>
- 327 7. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, et al. Efficacy and safety of a recombinant
328 hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled,
329 phase 3 trial. *Lancet Lond Engl*. 2010 Sep 11;376(9744):895–902.
- 330 8. Zhang J, Zhang XF, Huang SJ, Wu T, Hu YM, Wang ZZ, et al. Long-term efficacy of a hepatitis E
331 vaccine. *N Engl J Med*. 2015 Mar 5;372(10):914–22.
- 332 9. WHO position paper on hepatitis E vaccines - May 2015 [Internet]. [cited 2023 Mar 7]. Available
333 from: <https://www.who.int/publications-detail-redirect/WER9018-185-200>
- 334 10. Weekly Epidemiological Record (WER), 17 December 2021, Vol. 96, No. 50 (pp. 613–632)
335 [EN/FR] - World | ReliefWeb [Internet]. [cited 2022 Sep 23]. Available from:
336 [https://reliefweb.int/report/world/weekly-epidemiological-record-wer-17-december-2021-vol-](https://reliefweb.int/report/world/weekly-epidemiological-record-wer-17-december-2021-vol-96-no-50-pp-613-632-enfr)
337 [96-no-50-pp-613-632-enfr](https://reliefweb.int/report/world/weekly-epidemiological-record-wer-17-december-2021-vol-96-no-50-pp-613-632-enfr)

- 338 11. Ciglenecki I, Rumunu J, Wamala JF, Nkemenang P, Duncker J, Nesbitt R, et al. The first
339 reactive vaccination campaign against hepatitis E. *Lancet Infect Dis.* 2022 Aug;22(8):1110–1.
- 340 12. Collins J, Westerveld R, Nelson KA, Rohan H, Bower H, Lazenby S, et al. ‘Learn from the
341 lessons and don’t forget them’: identifying transferable lessons for COVID-19 from meningitis A,
342 yellow fever and Ebola virus disease vaccination campaigns. *BMJ Glob Health.* 2021 Sep
343 1;6(9):e006951.
- 344 13. Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, et al. First Outbreak Response
345 Using an Oral Cholera Vaccine in Africa: Vaccine Coverage, Acceptability and Surveillance of
346 Adverse Events, Guinea, 2012. *PLoS Negl Trop Dis.* 2013 Oct 17;7(10):e2465.
- 347 14. Peckeu-Abboud L, Mangoni P, Chammam K, Kwete P, Mutombo Lupola P, Vanlerberghe V, et
348 al. Drivers of Routine and Outbreak Vaccination Uptake in the Western Democratic Republic of
349 Congo: An Exploratory Study in Ten Health Zones. *Vaccines.* 2022 Jul 1;10(7):1066.
- 350
- 351

352 **Table 1.** Vaccination campaign results and administrative coverage by round and by dose, Bentiu IDP
 353 camp, South Sudan, 2022.

	Dates	Target	Vaccinated	1 st dose	2 nd dose	3 rd dose	Administrative coverage
Round 1	22-30 March	26,848	24,469	24,469			91%
Round 2	19-26 April	26,848	25,434	5,573	19,861		95%
Round 3	4-25 October	26,848	30,264	9,722	6,249	14,293	113%
Total n		26,848	80,167	39,764	26,110	14,293	
Coverage %				148%	97%	53%	

354

355 **Table 2.** Survey sample population characteristics by sex, n=1,599.

	Female		Male		Overall	
	n	%	n	%	n	%
Age group (years)						
0-5	312	14.7	338	17.5	650	16.0
6-10	315	14.8	336	17.4	651	16.1
11-15	329	15.5	382	18.8	711	17.5
16-24	464	21.8	425	22.0	889	21.9
25-40	485	22.8	295	15.3	780	19.2
41+	220	10.4	156	8.1	376	9.3
Total	2125	100	1932	99.1	4057	100
Pregnant¹						
No	1049	89.8	0	0	1049	89.8
Yes	119	10.2	0	0	119	10.2
Trimester of pregnancy						
1	23	19.3	0	0	23	19.3
2	50	42.0	0	0	50	42.0
3	46	3.7	0	0	46	3.7
Education²						
None	808	38.0	265	13.7	1073	26.5
Primary	300	14.1	355	18.4	655	16.1
Secondary	60	2.8	226	11.7	286	7.1
University	1	0.05	30	1.6	31	0.76
NA	956	45.0	1056	54.7	2012	49.6
Employment						
Cook	9	1.0	2	0.3	11	0.7
Driver	0	0	1	0.2	1	0.06
Logistics	0	0	6	0.9	6	0.4
Health or medical	1	0.1	9	1.4	10	0.6
Student	43	4.6	75	11.4	118	7.4
Unemployed	878	93.3	546	83.0	1424	89.1
Unknown	1	0.1	1	0.2	2	0.1
Survey respondent						
Delegate	1615	76.0	1774	92.0	3383	83
Self	508	23.9	158	8.2	666	16.4
Unknown	2	0.1	0	0	2	0.05
Hepatitis E Vaccination card³						
None	484	51.4	471	71.6	955	59.7
>= 1	457	48.6	187	28.4	644	40.3

¹women of childbearing age 14-45 years old; ²adults >= 16 years; ³ individuals 16-40 years old with known vaccination status

356

357

358 **Table 3.** Vaccination coverage by dose according to recall and confirmed by card, n=1,599.

Coverage by dose	According to recall or card			Confirmed by card		
	% (n)	95 % CI	DEFF	% (n)	95 % CI	DEFF
One or more doses	86% (1377)	[84-88]	1.6	40% (644)	[37-43]	1.8
Two or more doses	73% (1160)	[70-75]	1.6	19% (305)	[17-21]	1.3
Three doses	58% (924)	[55-61]	1.7	10% (163)	[9-12]	1.2

Note that confirmed by card means that all doses reported were verified on vaccination card and those without a card were considered unvaccinated.

359

Table 4. Vaccination coverage according to recall stratified by sex, pregnancy status, age group and sector, n=1,599.

	One or more doses			Two or more doses			Three doses		
	% (n)	95 % CI	DEFF	% (n)	95 % CI	DEFF	% (n)	95 % CI	DEFF
Sex									
Male	85% (557)	[81-88]	1.6	72% (471)	[67-76]	1.7	61% (399)	[56-65]	1.7
Female	87% (820)	[85-90]	1.3	73% (689)	[70-76]	1.4	56% (525)	[52-60]	1.4
p-value	0.20			0.55			0.10		
Pregnancy									
Pregnant	84% (98)	[76-90]	1.0	66% (77)	[57-74]	1.0	44% (51)	[34-53]	1.1
Not pregnant	88% (721)	[85-90]	1.2	74% (611)	[71-78]	1.3	58% (474)	[54-61]	1.3
p-value	0.23			0.05			0.006		
Age group									
[16,20]	88.0% (541)	[85-91]	1.3	71.5% (440)	[67-76]	1.4	56.9% (350)	[52-62]	1.4
(20,25]	83.0% (264)	[78-88]	1.3	69.5% (221)	[64-75]	1.3	55.7% (177)	[49-62]	1.4
(25,30]	83.9% (193)	[79-89]	1.2	70.4% (162)	[64-77]	1.1	55.7% (128)	[49-63]	1.2
(30,35]	84.6% (148)	[79-90]	1.1	75.4% (132)	[69-82]	1.1	62.9% (110)	[56-70]	1.0
(35,40]	88.5% (231)	[85-93]	1.1	78.5% (205)	[74-84]	1.0	60.9% (159)	[55-67]	1.0
p-val	0.43			0.18			0.17		
Sector									
Sector 1	83% (193)	[74-90]	2.6	70% (162)	[60-78]	2.2	55% (127)	[46-64]	2.0
Sector 2	83% (233)	[76-88]	1.6	66% (185)	[59-72]	1.4	52% (147)	[45-59]	1.5
Sector 3	90% (357)	[86-93]	1.2	76% (301)	[71-80]	1.3	63% (251)	[57-69]	1.5
Sector 4	85% (215)	[78-90]	1.7	70% (179)	[62-78]	2.1	53% (134)	[44-61]	2.0
Sector 5	87% (379)	[83-90]	1.3	77% (333)	[72-81]	1.3	61% (265)	[55-67]	1.7
p-value	0.19			0.078			0.088		

Table 5. Reasons for non-vaccination by number of doses received.

Reasons for non-vaccination	0 doses		1 dose		2 doses	
Physical absence	133	59.6%	176	80.7%	179	76.8%
I was living in Bentiu IDP camp but was temporarily away	62	27.8%	109	50.0%	129	55.4%
I was not living in Bentiu IDP camp during the vaccination	46	20.6%	60	27.5%	27	11.6%
I was living in Bentiu IDP camp but not available during the hours	25	11.2%	7	3.2%	23	9.9%
Campaign awareness or organisation	9	4.0%	6	2.8%	2	0.9%
I did not know about the vaccination campaign	7	3.1%	5	2.3%	1	0.4%
I did not think that I was eligible for vaccination	2	0.9%	1	0.5%	1	0.4%
I went to the vaccination site but there was no vaccine	0	0.0%	0	0.0%		0.0%
Health issues	11	4.9%	6	2.8%	25	10.7%
I was sick during the vaccination campaign	8	3.6%	5	2.3%	21	9.0%
I went to the site but could not get vaccinated due to my health	3	1.3%	1	0.5%	4	1.7%
Fears and concerns	39	17.5%	17	7.8%	17	7.3%
I am afraid of needles	13	5.8%	11	5.0%	5	2.1%
I already received too many vaccines	9	4.0%	1	0.5%	2	0.9%
I am worried about side effects	4	1.8%	4	1.8%	7	3.0%
I think the vaccine is dangerous	6	2.7%	0	0.0%	1	0.4%
I do not think getting sick with hepatitis E is serious	6	2.7%	0	0.0%	1	0.4%
I am worried that the vaccine will affect my fertility in the future	1	0.4%	1	0.5%	0	0.0%
My spouse / decision maker refused the vaccination	0	0.0%	0	0.0%	1	0.4%
I have religious concerns	0	0.0%	0	0.0%	0	0.0%
Other						
Refused with no reason given	32	14.3%	13	6.0%	11	4.7%
Unknown	8	3.6%	1	0.5%	0	0.0%
Other	4	1.8%	2	0.9%	2	0.9%
Total n	223		218		233	

Non-mutually exclusive categories, individuals may have given more than one reason.

Table 6. Symptoms reported after dose of Hecolin vaccine in October 2022, n=91 individuals reported symptoms after vaccination (each individual may have reported more than one symptom) among N= 1,195 individuals vaccinated.

	n	%	Incidence per 100*
Local reactions	17		1.42%
Local swelling around injection site	2	2.2%	0.17%
Local pain around injection site	11	12.1%	0.92%
Local itch around injection site	1	1.1%	0.08%
Redness around injection site	0	0.0%	0.00%
Rash	3	3.3%	0.25%
Systemic reactions	140		11.72%
Fever	68	74.7%	5.69%
Headache	29	31.9%	2.43%
Fatigue and general weakness	21	23.1%	1.76%
Cough	5	5.5%	0.42%
Muscle aches	9	9.9%	0.75%
Nausea and/or vomiting	2	2.2%	0.17%
Diarrhea	5	5.5%	0.42%
Other, specify	14	15.4%	1.17%

Non-mutually exclusive, individuals reported more than one symptom.

**calculated as n reporting symptom / total N vaccinated in third round.*




Figure 1. Vaccination coverage according to recall by dose and age group.

Appendix

Table A1. Vaccination coverage with exact number of doses according to recall and by card, n=1599.

Coverage by dose	According to recall			Confirmed by card		
	% (n)	95 % CI	DEFF	% (n)	95 % CI	DEFF
None	13.9% (222)	[12-16]	1.6	59.7% (955)	[57-63]	1.7
One dose	13.6% (217)	[12-16]	1.3	21.2% (339)	[18.9-23.7]	1.5
Two doses	14.8% (236)	[13-17]	1.2	8.9% (142)	[7.5-10.5]	1.2
Three doses	57.8% (924)	[55-61]	1.7	10.2% (163)	[8.7-12.0]	1.2

Note that confirmed by card means that specific doses reported were verified on vaccination card.

Table A2. Sensitivity analysis including only those who self-reported, n=513.

Coverage by dose	According to recall or card			Confirmed by card		
	% (n)	95 % CI	DEFF	% (n)	95 % CI	DEFF
One or more doses	89% (457)	[86-92]	1.2	58% (296)	[53-57]	1.2
Two or more doses	74% (378)	[69-78]	1.4	32% (162)	[27-36]	1.1
Three doses	58% (297)	[53-63]	1.2	19% (96)	[15-22]	1.2

Note that confirmed by card means that all doses reported were verified on vaccination card.

Table A3. Sensitivity analysis vaccination coverage by dose according to recall and card, n=1470 individuals 16-39 yrs.

Coverage by dose	According to recall or card			Confirmed by card		
	% (n)	95 % CI	DEFF	% (n)	95 % CI	DEFF
One or more doses	85% (1255)	[83-88]	1.6	38% (558)	[35-41]	1.7
Two or more doses	72% (1056)	[69-75]	1.7	18% (258)	[15-20]	1.2
Three doses	57% (845)	[54-61]	1.7	9% (135)	[8-11]	1.2

Note that confirmed by card means that all doses reported were verified on vaccination card.

Figure A1. Population pyramid for all individuals counted at randomly selected households (L) and vaccine-eligible individuals counted at randomly selected households (R).

